AN 215
Alternative Names: AN-215Latest Information Update: 08 Aug 2024
At a glance
- Originator AEterna Zentaris Inc; Tulane University School of Medicine; Zentaris
- Developer AEterna Zentaris GmbH; Tulane University School of Medicine
- Class Antineoplastics
- Mechanism of Action DNA intercalators; Gastrin-releasing peptide inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
- 06 Oct 2008 Discontinued - Preclinical for Solid tumours in USA (IV)
- 01 Jun 2006 This compound is still in active development